Raymond James & Associates Buys 33,414 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Raymond James & Associates lifted its stake in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 200.9% in the 4th quarter, Holdings Channel reports. The fund owned 50,047 shares of the company’s stock after acquiring an additional 33,414 shares during the quarter. Raymond James & Associates’ holdings in Option Care Health were worth $1,686,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in OPCH. American Century Companies Inc. acquired a new position in Option Care Health during the first quarter worth $907,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Option Care Health during the first quarter worth $500,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Option Care Health by 10.5% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,760 shares of the company’s stock worth $1,450,000 after purchasing an additional 4,840 shares during the last quarter. Great West Life Assurance Co. Can boosted its holdings in Option Care Health by 8.2% during the first quarter. Great West Life Assurance Co. Can now owns 74,363 shares of the company’s stock worth $2,181,000 after purchasing an additional 5,637 shares during the last quarter. Finally, Yousif Capital Management LLC boosted its holdings in Option Care Health by 1.8% during the first quarter. Yousif Capital Management LLC now owns 77,343 shares of the company’s stock worth $2,209,000 after purchasing an additional 1,349 shares during the last quarter. Institutional investors own 98.05% of the company’s stock.

Option Care Health Stock Performance

Shares of OPCH stock opened at $30.27 on Thursday. The stock has a market cap of $5.26 billion, a P/E ratio of 20.59, a P/E/G ratio of 1.76 and a beta of 1.22. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.77 and a quick ratio of 1.33. The company has a fifty day moving average price of $32.34 and a two-hundred day moving average price of $31.59. Option Care Health, Inc. has a one year low of $24.23 and a one year high of $35.74.

Option Care Health (NASDAQ:OPCH) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.03. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Option Care Health had a net margin of 6.21% and a return on equity of 18.78%. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.26 earnings per share. As a group, equities analysts predict that Option Care Health, Inc. will post 1.13 EPS for the current year.

Insider Transactions at Option Care Health

In related news, Director Harry M. Jansen Kraemer, Jr. bought 35,000 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was bought at an average price of $31.55 per share, for a total transaction of $1,104,250.00. Following the purchase, the director now owns 269,528 shares in the company, valued at approximately $8,503,608.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.64% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

OPCH has been the subject of several recent research reports. Jefferies Financial Group increased their target price on shares of Option Care Health from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Barrington Research increased their target price on shares of Option Care Health from $35.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, February 23rd.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.